Sonelokimab is a novel trivalent nanobody comprised of monovalent camelid-derived nanobodies specific to human interleukin IL-17A, IL-17F, and human serum albumin. Sonelokimab has been used in the research of plaque psoriasis.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.